Dr. Li-Huei Tsai and Dr. Ed Boyden discovered gamma oscillation entrainment as a non-invasive approach to modulating abnormal electrophysiology. This approach was validated translationally to neuronal pathophysiology that effects disease modification in mild-cognitive impairment and Alzheimer’s disease. This particular treatment addressed novel targets (neuronal pathophysiologies) and improved functional outcomes. This was demonstrated in 3 phase II trials which indicated improvements in memory, cognition, functional symptoms, and reduction of brain atrophy. This platform has also demonstrated high safety, tolerability, and adherence with patients. The platform was given FDA Breakthrough Designation, paving the way for approval in 2025. This therapy addresses a space with high unmet need and shows a pathway to other indications with high unmet need, with the opportunity for concomitant treatments (no drug-drug interactions).